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Abstract: The role of different genotypes of apolipoprotein E (apoE) in the etiology of Alzheimer’s
disease is widely recognized. It has been shown that altered functioning of apoE may promote
4-hydroxynonenal modification of mitochondrial proteins, which may result in mitochondrial
dysfunction, aggravation of oxidative stress, and neurodegeneration. Mitochondrial aldehyde
dehydrogenase (ALDH2) is an enzyme considered to perform protective function in mitochondria
by the detoxification of the end products of lipid peroxidation, such as 4-hydroxynonenal and other
reactive aldehydes. The goal of our study was to apply a differential proteomics approach in concert
with molecular and morphological techniques to elucidate the changes in the frontal cortex and
hippocampus of apolipoprotein E knockout (apoE−/−) mice upon treatment with Alda-1—a small
molecular weight activator of ALDH2. Despite the lack of significant morphological changes in
the brain of apoE−/− mice as compared to age-matched wild type animals, the proteomic and
molecular approach revealed many changes in the expression of genes and proteins, indicating the
impairment of energy metabolism, neuroplasticity, and neurogenesis in brains of apoE−/− mice.
Importantly, prolonged treatment of apoE−/− mice with Alda-1 led to the beneficial changes in the
expression of genes and proteins related to neuroplasticity and mitochondrial function. The pattern
of alterations implies mitoprotective action of Alda-1, however, the accurate functional consequences
of the revealed changes require further research.
Keywords: ALDH2; mitochondria; Alzheimer’s disease; apolipoprotein E; brain
1. Introduction
Alzheimer’s disease (AD) is the most widespread neurodegenerative disorder in the elderly,
characterized by irreversible loss of cortical neurons associated with the accumulation of β-amyloid
deposits and neurofibrillary tangles (NFTs) formed by aggregates of hyperphosphorylated Tau
protein [1,2]. It has been recently shown that oxidative stress and multi-faceted dysfunction of
mitochondria take part in the pathogenesis of neurodegeneration [3,4]. Indeed, impaired energy
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metabolism with decreased activity of mitochondrial electron transport chain enzymes (mainly
complex I and IV) and citric acid cycle enzymes (pyruvate dehydrogenase complex, α-ketoglutarate
dehydrogenase complex) as well as an increased number of mitochondrial DNA mutations,
accompanied by augmented mitochondrial reactive oxygen species (ROS) formation have been
observed in animal models of neurodegeneration [4] and in AD patients [5,6]. It has been shown that
the ROS-dependent lipid peroxidation results in the generation of electrophilic aldehydes such as
4-hydroxy-2-nonenal (4-HNE), malondialdehyde (MDA), and acrolein, which may fervently react
with thiols and amino acid residues in proteins. Importantly, it has been observed, that 4-HNE
could mediate oxidation of major mitochondrial proteins (e.g., electron transport chain and citric acid
enzymes or its cofactors such as lipoic acid) [7]. Moreover, 4-HNE and accumulation of its protein
adducts were implicated in mitochondrial dysfunction and have been postulated to play a role in
neurodegenerative processes [8–10].
Mitochondrial aldehyde dehydrogenase (ALDH2) plays a main role in the degradation of
aldehydes to corresponding non-toxic acids [11]. N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichloro
-benzamide (Alda-1) is a cell-permeable, small molecular weight activator of ALDH2 [12]. It has been
observed that Alda-1 administration shows beneficial action in diseases linked to mitochondrial
dysfunction (e.g., acute ischemic injury in the heart [13], atherosclerosis and hepatic steatosis [14],
diabetes-induced myocardial dysfunction [15], and parkinsonism [16]). Recently, we have
demonstrated attenuation of depressive- and anxiety-like behaviors by Alda-1 in rat model of
depression [17]. Interestingly, it has also been reported that pharmacological activation of ALDH2
prevents dysfunction of endothelial cells induced by β-amyloid in vitro [18]. However, there is no
information whether prolonged ALDH2 activation by Alda-1 may offer any benefits in animal models
of neurodegeneration.
Apolipoprotein E (apoE) is a glycoprotein mainly expressed by brain, liver, spleen, lung, adrenal,
ovary, kidney, and muscle. In the brain it is predominantly synthetized by astrocytes and microglia, and
involved in cholesterol transport as well as in the development and regeneration of the central nervous
system (CNS) [19]. The presence of epsilon4 allele of apoE (apoE4) was found to predispose to the
development of AD, possibly by impairing proteolytic break-down of β-amyloid [20]. Interestingly, it
has also been shown that apoE4 may augment 4-HNE-dependent modification of mitochondrial
proteins and cause mitochondrial dysfunction [21,22]. The apoE knockout mice (apoE−/−) are
primarily used in atherosclerosis studies since they spontaneously develop hypercholesterolemia,
dyslipidemia, and arterial lesions [23,24]. They are not considered as a model of full-blown Alzheimer’s
disease, however, they have been shown to develop several neurodegenerative changes relevant to
the early stages of AD, such as low-grade synaptic and dendrite loss as well as behavioral alterations
and deficits in long-term potentiation (LTP) [25,26]. Importantly, despite such delicate morphological
alterations, some biochemical disturbances—increased ROS formation and lipid peroxidation—have
been clearly demonstrated in brains of apoE−/− mice [27].
Proteomics represents a valuable tool for the study of mitochondrial pathobiology and
may contribute to the better understanding of mitochondrial mechanisms of neurodegenerative
disorders [28]. However, so far the proteomic research has not been used to evaluate the changes in the
brain mitochondria in apoE−/− mice. Thus, the goal of our study was to apply a differential proteomics
approach in concert with molecular and morphological techniques to elucidate the changes in the
mitochondria-enriched fractions isolated from the frontal cortex and hippocampus of apoE−/− mice
as compared to age-matched wild type animals and in apoE−/− mice upon treatment with Alda-1.
2. Results
2.1. Biochemistry Results
To assess the Alda-1 action in apoE−/− mice, we measured the changes in 4-HNE levels by an
enzyme-linked immunosorbent assay (ELISA). Importantly, Alda-1 treatment resulted in a significant
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decrease of 4-HNE-protein content in the plasma (0.27 vs. 0.44 pmol; F(2,6) = 97.78; p < 0.05) and FC
(11.91 vs. 19.41 pmol/g; F(2,6) = 10.53; p < 0.05) of apoE−/− mice (Figure 1). In addition we observed
an increase of 4-HNE-protein content in the plasma (0.44 vs. 0.3 pmol; F(2,6) = 169.81; p < 0.05) of
apoE−/− mice as compared to control mice (Figure 1).
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associated protein 2 (MAP2) (marker of dendrites), and Tau and phospho-Tau (Ser396) (marker of 
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2.3. mRNA Expression of Factors Related to Mitochondrial Biogenesis, Apoptosis, Inflammation,  
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Figure 1. The level of 4-hydroxy-2-nonenal (4-HNE)-protein adducts in the plasma and the frontal
cortex of control mice, apolipoprotein E (apoE)−/− mice and Alda-1-treated apoE−/− mice. The data
are presented as the mean ± SEM, with n = 3 for each group. * p < 0.05 vs. control group; # p < 0.05 vs.
apoE−/− group.
2.2. Histology and Immunohistochemistry Results
Hematoxylin/eosin (HE) staining did not reveal any major changes in the brain structures
in control mice, apoE−/− mice, and Alda-1-treated apoE−/− mice. However, apoE−/− mice as
compared to wild type animals exhibited signs of the mild tissue injury: some neurons were shrunken
and deeply stained (“dark neurons”). These changes were visually slightly less pronounced in
brains of Alda-1-treated apoE−/− mice (Figure 2A–C). Immunohistochemistry staining of β-amyloid,
microtubule-associated protein 2 (MAP2) (marker of dendrites), and Tau and phospho-Tau (Ser396)
(marker of neurofibrillary tangles) did not show any differences between brain structures of wild type
mice, apoE−/− mice, and Alda-1-treated apoE−/− mice (Figure 2D–O).
2.3. mRNA Expression of Factors Related to Mitochondrial Biogenesis, Apoptosis, Inflammation,
and Neuroplasticity
We measured the mRNA expression of selected, important factors related to mitochondrial
biogenesis (PGC1-α, Tfam, Nrf1, CYTB, COX1, COX3, ND1, ND4, ATP6), apoptosis (Bax, Bcl-2, Bcl2l1,
Casp8, Casp9, Casp3), inflammation (IL-1β, IL-6, NF-κB), neuroplasticity (Bdnf, Nog, Bmp4), and the
pathogenesis of Alzhe mer disease (Cdk5, Cdk5r1, Gsk3a Gsk3b) in the hippocampus and the fron al
cor ex of C57BL/6J mice, apoE−/− mice, and Alda-1-treated apoE−/− mice. B th in the frontal cortices
(FCx) and the hippocampi (Hp) of apoE−/− mice as comp red to controls we observed significant
decreases in g nes expression related to neurogen sis (Bdnf, Nog). In additi n, apoE−/− mice exhibited
cr s d Bcl-2 and N f1 mRNA expression in th Hp a d the FCx, respectively (Table 1). Alda-1
admini tration led to a slight increase in gene expression related to neurogenes s (Nog), mitochondrial
bioge e is (CYTB, ND1), and apoptosis (Bax, Gsk3b) in the Hp of apoE−/− mice (Table 2). I the FCx of
apoE−/− mice, Alda-1 treatment resulted in the reduction of Bmp4 mRNA ex ression (Table 2).
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Table 1. The statistically significant differences in the relative gene expression between apoE−/− group
vs. wild type animals in the hippocampus and the frontal cortex (p < 0.05, n = 3).
Gene Name Description Fold Change p-Value
The Hippocampus
Bcl-2 B-cell lymphoma 2 −1.30 0.0467
Bdnf Brain-derived neurotrophic factor −1.27 0.0278
Bmp4 Bone morphogenetic protein 4 −1.69 0.0091
Nog Noggin −1.41 0.0096
The Frontal Cortex
Bdnf Brain-derived neurotrophic factor −1.29 0.0448
Nog Noggin −1.39 0.0174
Nrf1 Nuclear respiratory factor 1 −1.21 0.0096
Table 2. The statistically significant differences in the relative gene expression between Alda-1-treated
apoE−/− group vs. untreated apoE−/− group in the hippocampus and the frontal cortex (p < 0.05,
n = 3).
Gene Name Description Fold Change p-Value
The Hippocampus
Bax Bcl-2-like protein 4 1.22 0.0303
CYTB Cytochrom b 1.33 0.0258
Gsk3b Glycogen synthase kinase 3β 1.24 0.0058
ND1 Mitochondrially encoded NADH dehydrogenase 1 1.35 0.0312
Nog Noggin 1.20 0.0268
The Frontal Cortex
Bmp4 Bone morphogenetic protein 4 −1.28 0.0366
2.4. Mitochondrial Protein Expression Assessed by iTRAQ Method
We investigated mitochondrial protein expression in the FCx and the Hp of control mice,
apoE−/− mice, and Alda-1-treated apoE−/− mice using isobaric tag for relative quantitation (iTRAQ
method). Collectively, 20 and 34 differentially expressed proteins in the FCx and Hp of apoE−/− mice,
respectively, were detected by iTRAQ/mass spectrometry, as compared to control group (Tables 3
and 4). Alda-1 administration led to 2 and 10 differentially expressed proteins in the FCx and Hp of
apoE−/− mice, respectively (Tables 5 and 6).
Table 3. Differentially expressed proteins in the frontal cortex mitochondria of apoE−/− group vs. wild
type animals (p < 0.05, n = 3).
No. Protein UniProtKBAccession No.
Unique
Peptides
Total
Peptides
Fold
Change
1 Microtubule-actin cross-linking factor 1 Q9QXZ0 2 2 1.59
2 AP-3 complex subunit δ-1 O54774 2 8 1.30
3 Cytochrome b-c1 complex subunit 7 Q9D855 2 3 1.28
4 Histone H4 P62806 6 28 1.26
5 ATP-dependent 6-phosphofructokinase, muscle type P47857 6 15 1.24
6 Myelin basic protein P04370 10 235 1.18
7 Metabotropic glutamate receptor 3 Q9QYS2 4 8 1.18
8 Tubulin β-3 chain Q9ERD7 12 130 1.11
9 Spectrin α chain, non-erythrocytic 1 P16546 89 416 1.06
10 Tubulin β-4 B chain P68372 11 356 1.06
11 Calcium-binding mitochondrial carrier protein Aralar1 Q8BH59 15 73 −1.13
12 NADH dehydrogenase (ubiquinone) flavoprotein 1, mitochondrial Q91YT0 7 18 −1.19
13 Pyruvate carboxylase, mitochondrial Q05920 2 5 −1.21
14 Solute carrier family 12 member 5 Q91V14 10 46 −1.23
15 Dynein light chain 1, cytoplasmic P63168 5 17 −1.23
16 Succinyl-CoA ligase (ADP/GDP-forming) subunit α, mitochondrial Q9WUM5 3 25 −1.26
17 Ubiquitin-60S ribosomal protein L40 P62984 5 57 −1.26
18 Cytochrome c oxidase subunit 7A2, mitochondrial P48771 2 7 −1.33
19 Basigin P18572 2 4 −1.41
20 Proline-rich transmembrane protein 2 E9PUL5 2 5 −1.72
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Table 4. Differentially expressed proteins in the hippocampus mitochondria of apoE−/− group vs.
wild type animals (p < 0.05, n = 3).
No. Protein UniProtKBAccession No.
Unique
Peptides
Total
Peptides
Fold
Change
1 Coronin-2B Q8BH44 2 3 1.73
2 Protein deglycase DJ-1 Q99LX0 5 20 1.32
3 Synaptoporin Q8BGN8 4 8 1.23
4 ATP synthase subunit δ, mitochondrial Q9D3D9 3 18 1.23
5 Spectrin β chain, erythrocytic P15508 3 9 1.23
6 MICOS complex subunit Mic25 Q91VN4 2 3 1.21
7 Ubiquitin-60S ribosomal protein L40 P62984 4 51 1.21
8 Tubulin α-1 chain A2AQ07 7 33 1.17
9 Tropomyosin α-3 chain P21107 3 16 1.17
10 Paralemmin-1 Q9Z0P4 7 33 1.16
11 Disks large homolog 4 Q62108 5 19 1.14
12 Pyruvate dehydrogenase E1 component subunit β, mitochondrial Q9D051 16 86 1.14
13 Creatine kinase B-type Q04447 19 306 1.11
14 Calcium/calmodulin-dependent protein kinase type II subunit α P11798 25 329 1.10
15 Tubulin β-4 B chain P68372 11 249 1.09
16 Heat shock cognate 71 kDa protein P63017 37 351 1.08
17 Hexokinase-1 P17710 33 246 1.07
18 Spectrin β chain, non-erythrocytic 1 Q62261 72 351 1.07
19 ADP/ATP translocase 1 P48962 22 217 −1.11
20 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β-1 P62874 12 134 −1.11
21 Calcium-dependent secretion activator 1 Q80TJ1 16 56 −1.14
22 Fumarate hydratase, mitochondrial P97807 10 38 −1.15
23 Glutathione S-transferase Mu 1 P10649 15 76 −1.15
24 Dihydropyrimidinase-related protein 1 P97427 8 32 −1.15
25 Thioredoxin P10639 3 11 −1.18
26 Ras-related protein Rab-1A P62821 6 46 −1.20
27 Actin-related protein 2 P61161 6 13 −1.24
28 Mitochondrial 2-oxoglutarate/malate carrier protein Q9CR62 6 16 −1.26
29 Heterogeneous nuclear ribonucleoprotein K P61979 3 13 −1.28
30 α-endosulfine P60840 2 3 −1.30
31 Calcium/calmodulin-dependent protein kinase type IV P08414 2 4 −1.34
32 Guanine nucleotide-binding protein G(i) subunit α-2 P08752 4 13 −1.37
33 Myelin basic protein P04370 11 138 −1.43
34 2′ ,3′-cyclic-nucleotide 3′-phosphodiesterase P16330 32 210 −1.47
Table 5. Differentially expressed proteins in the frontal cortex mitochondria of Alda-1-treated apoE−/−
group vs. untreated apoE−/− group (p < 0.05, n = 3).
No. Protein UniProtKBAccession No.
Unique
Peptides
Total
Peptides
Fold
Change
1 NADH dehydrogenase ubiquinone 1α subcomplexsubunit 10, mitochondrial Q99LC3 5 10 1.27
2 Excitatory amino acid transporter 2 P43006 12 111 1.12
Table 6. Differentially expressed proteins in the hippocampus mitochondria of Alda-1-treated apoE−/−
group vs. untreated apoE−/− group (p < 0.05, n = 3).
No. Protein UniProtKBAccession No.
Unique
Peptides
Total
Peptides
Fold
Change
1 Myelin basic protein P04370 11 123 1.37
2 Carbonic anhydrase 2 P00920 4 24 1.27
3 Myelin proteolipid protein P60202 4 48 1.25
4 2′ ,3′-cyclic-nucleotide 3′-phosphodiesterase P16330 22 141 1.25
5 Sodium/potassium-transporting ATPase subunit α-2 Q6PIE5 22 180 1.11
6 Excitatory amino acid transporter 2 P43006 15 183 1.09
7 Spectrin β chain, non-erythrocytic 1 Q62261 64 303 −1.06
8 Spectrin α chain, non-erythrocytic 1 P16546 98 606 −1.06
9 Actin, aortic smooth muscle P62737 24 182 −1.09
10 OCIA domain-containing protein 2 Q9D8W7 2 7 −1.40
3. Discussion
Several lines of evidence suggest that altered functioning of apoE may aggravate aldehyde
modification of mitochondrial proteins, which may result in mitochondrial dysfunction and
neurodegeneration [5,6,21]. In the present work, we focused on the effect of Alda-1 activation of
ALDH2—an enzyme responsible for the detoxification of toxic aldehydes—on the protein content of
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mitochondria-enriched fractions isolated from the frontal cortex and hippocampus of apolipoprotein
E knockout mice (apoE−/−). Moreover, the proteomic approach was supported by molecular and
morphological techniques. This is the first report about the molecular and proteomic effects of
pharmacological activation of ALDH2 in CNS structures in apoE−/− mice. The main finding of our
study is that Alda-1 administration led to the beneficial changes in the expression of genes and proteins
related to neuroplasticity and mitochondrial function.
Although the most recognized function of mitochondrial ALDH2 is the degradation of
acetaldehyde in the metabolism of ethanol, it can also efficiently oxidize other reactive aldehydes,
especially 4-HNE, to non-toxic acids. Indeed, in our hands, Alda-1 caused a significant decrease in
4-HNE-protein content in the plasma and the frontal cortex of apoE−/− mice, which might depend
on ALDH2 activation. However, the exact confirmation of Alda-1 influence on ALDH2 activity
regarding the metabolism of 4-HNE to related acids does require further investigations including
direct measurements of ALDH2 activity and tissue levels of corresponding acids.
In line with some previous reports [25,26], we observed delicate signs of the nonspecific mild
tissue injury in brains of apoE−/− mice. The number of shrunken and deeply stained neurons (“dark
neurons”) was higher in brains apoE−/− mice. It should be noted however, that the presence of
such changes may depend on the lot of animals, as they were absent in apoE−/− mice studied by
Anderson et al. [29]. Moreover, according to some reports, the dark neurons may rather reflect
histological artifacts than trustworthy markers of tissue injury [30]. In keeping with the majority of
reports [25,26], we did not reveal any changes in tissue contents of β-amyloid, Tau, p-Tau (Ser396),
and microtubule-associated protein 2 (MAP2). In our study, we focused on the changes on the levels of
the gene/protein expression occurring in the absence of morphologically overt tissue injury.
A growing amount of evidence points to the impairment of neuroplasticity in the pathogenesis
of Alzheimer's disease [31–33]. Importantly, mitochondria perform a key role in the regulation of
neuroplasticity and maintenance of cellular calcium homeostasis [34]. Brain-derived neurotrophic
factor (BDNF) is a main regulator of synaptic plasticity, long-term memory, as well as neuronal survival
and differentiation [35,36]. Moreover, BDNF is able to streamline mitochondrial respiratory coupling
and increase ATP synthesis [37]. Interestingly, it has been observed that lower levels of BDNF in
the plasma and the cerebrospinal fluid were presented in the early stages of AD and mild cognitive
impairment (MCI) [38]. In keeping with these reports, we showed diminished Bdnf mRNA expression
in the FCx and Hp of apoE−/− mice, as compared to wild type animals. In turn, noggin (NOG) and
bone morphogenetic protein 4 (BMP4) have been recognized as potent regulators of neurogenesis. It is
known that BMP4 is related to decreased neurogenesis and increased gliogenesis, while expression of
BMP4 inhibitor, NOG, is linked to increased neurogenesis [39] and therefore plays a significant role
in the process of learning and memory [40]. Disturbances in hippocampal neurogenesis have been
connected to memory deficits and cognitive impairment in the early stages of AD [41]. In this study,
Nog mRNA expression was decreased both in the FCx and Hp of apoE−/− mice. Importantly, Alda-1
administration led to the increase in Nog mRNA expression in the Hp and the decrease in Bmp4 mRNA
expression in the FCx.
Proteomic analysis using iTRAQ and mass spectrometry methods also revealed changes in
protein expression related to the impairment of neuroplasticity in the Hp of apoE−/− mice: we
observed decreased expression of collapsin response mediator protein 1 (CRMP1), heterogeneous
nuclear ribonucleoprotein K (hnRNP K), calcium-dependent secretion activator 1 (CAPS-1), and
2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP). CRMP1 is involved in axonal growth and long-term
potentiation (LTP) [42], whereas hnRNP K regulates neurite outgrowth, dendritic spine density, and
synaptic plasticity in hippocampal neurons [43,44]. In turn, CAPS-1 is a calcium-binding protein
engaged in exocytosis of neurotransmitters and neuropeptides, while CNP is required for proper
axoglial interactions [45]. Decreased CNP expression, observed in entorhinal and auditory cortex of
AD patients, might suggest the impairment in myelination with subsequent synaptic and cognition
loss [46]. It is worth highlighting that in our study CNP was a common protein differentially expressed
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in the Hp of control mice, apoE−/− mice, and apoE−/− mice treated with Alda-1. Importantly, Alda-1
administration up-regulated CNP expression, which may denote its beneficial action in the early stages
of AD.
It is well known that a major hallmark of Alzheimer’s disease is the loss of short and long-term
memory [13]. Interestingly, we noted down-regulation of calcium/calmodulin-dependent protein
kinase type IV (CaMK IV) and basigin (CD147) in the Hp and FCx of apoE−/− mice, respectively.
CaMK IV has been demonstrated to participate in the activation of CREB transcription factor, thereby
regulating genes responsible for memory and neuronal survival [47]. It can also perform a protective
role against neuronal injury [48,49]. In turn, glycoprotein CD147 may regulate the activity of β-amyloid
processing enzyme, γ-secretase. It was shown that mice deficient in CD147 showed deficits in memory
and spatial learning [50]. It might well be that the decreased expression of the aforementioned proteins
could be linked to learning and memory impairment observed in apoE−/− mice in the Morris water
maze test [51]. In our case, treatment with Alda-1 resulted in the increase in carbonic anhydrase 2
(CA2) expression in the Hp of apoE−/− mice. Interestingly, CA2 has been postulated to modulate
hippocampal CA1 neuronal network activity and its downregulation may result in impaired cognition.
Moreover, use of CA2 activators has been shown to improve learning and memory [52]. In this regard,
Alda-1 activity toward increase of CA2 might represent promising area of research.
A growing amount of evidence points to the presence of mitochondrial dysfunction manifested
by energy metabolism impairment and decreased activity of oxidative phosphorylation (OXPHOS)
and Krebs cycle enzymes both in animal models of AD and in patients [5,6,53]. Similarly, mostly in
the FCx of apoE−/− mice, we have observed diminished expression of OXPHOS proteins (NADH
dehydrogenase flavoprotein 1, cytochrome C oxidase subunit 7A2), proteins supporting OXPHOS
(mitochondrial aspartate glutamate carrier 1), and proteins involved in Krebs cycle (succinyl-CoA
synthetase subunit α, fumarate hydratase). On the other hand, proteins participating in glycolysis
(6-phosphofructokinase type A, hexokinase-1) have been upregulated in the Hp and FCx of apoE−/−
mice. However, we have also revealed changes, which may be considered as contradictory: increased
expression of ATP synthase subunit δ and cytochrome b-c1 complex subunit 7 in the Hp and FCx of
apoE−/− mice, respectively. Clearly, further investigations are required to clarify an interpretation of
above effects.
Interestingly, in the FCx of apoE−/− mice we have found decreased mRNA expression of nuclear
respiratory factor 1 (Nrf1), which is a transcription factor responsible for the activation of expression of
many factors involved in energy metabolism, cellular respiration, and replication and transcription
of mitochondrial DNA [54]. Diminished expression of peroxisome proliferator-activated receptor
gamma coactivator 1-α (PGC-1α) and downregulation of Nrf1 mRNA have been attributed to the
impairment of mitochondrial biogenesis in transgenic mouse model of AD [53]. In our case, Alda-1
administration led to the increased expression of proteins that participated in OXPHOS at gene
(mitochondrially encoded NADH dehydrogenase 1 (ND1), cytochrom b (CYTB)), and protein level
(NADH dehydrogenase 1α subcomplex subunit 10) in the FCx of apoE−/− mice, which may suggest
the stimulation of mitochondrial biogenesis.
Recent reports emphasize the role of glutamate-mediated excitotoxicity in the pathogenesis of
neurodegenerative diseases, such as Alzheimer’s disease, Huntington disease, and amyotrophic
lateral sclerosis (ALS). Our results indicate that proline-rich transmembrane protein 2 (PRRT2)
was down-regulated in the FCx of apoE−/− mice. PRRT2 is a transmembrane protein found in
glutamatergic neurons, where it interacts with synaptosomal-associated protein 25 (SNAP25), which
inhibits glutamate release and neuronal hyperexcitability. Thus, diminished expression of PRRT2 may
lead to decreased interactions with SNAP25, which could potentially result in the increased release
of glutamate [55]. Importantly, Alda-1 administration led to the upregulation of excitatory amino
acid transporter 2 (EAAT2) both in the Hp and FCx of apoE−/− mice. EAAT2 is crucial for tuning
of the glutamate neurotransmission by its rapid removal from the synaptic cleft, thus maintaining
the levels of glutamate within safe range [56]. Moreover, it has been shown that reduced EAAT2
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function observed in AD is associated with cognitive decline and increased amyloid β production,
thus restoring EAAT2 protein function could represent a potential therapeutic approach in AD [57].
It is tempting to speculate that upregulation of EAAT2 by Alda-1 may denote its beneficial action in
the early stages of AD.
It is well recognized that oxidative stress plays a crucial role in the etiology and progression
of AD [58]. We have observed diminished expression of antioxidant proteins, such as glutathione
S-transferase Mu 1 (GST 1-1) and thioredoxin (TRX) in the Hp of apoE−/− mice. GST 1-1 is best
known for its ability to detoxify xenobiotics, including 4-HNE, by their conjugation with the reduced
form of glutathione (GSH). In turn, TRX acts as an antioxidant by maintaining the reduced form of
cellular thiols. Our results are in keeping with previous reports: it has been observed that the lack of
TRX2 impairs mitochondrial redox homeostasis and leads to early-onset neurodegeneration [59]; the
decreased activity of GST 1-1 has been detected in the Hp of AD patients [60].
Interestingly, some changes observed in apoE−/− mice may represent compensatory mechanisms,
for example, Parkinson disease protein 7 homolog (PARK7) was upregulated in the Hp of apoE−/−
mice. PARK7 plays multiple cellular roles as a modulator of gene transcription, an antioxidant protein,
and a regulator of mitochondrial functions. It can also regulate the activity of complex I in mitochondria
and exert a mitoprotective effect [61,62]. Mutations in PARK7 gene are associated with hereditary
Parkinson’s disease (PD) [63]. In addition, the increased level of oxidized (inactive) form of PARK7
has been detected in the brain of AD and PD patients [64]. The upregulation of PARK7 in the Hp of
apoE−/− mice might be interpreted as a compensatory mechanism, to counteract accelerated oxidative
stress and mitochondrial dysfunction presented in the early stages of AD. Similarly, the increase in
protein required for synaptic plasticity associated with NMDA receptor signaling-postsynaptic density
protein 95 (PSD-95) might represent a compensatory mechanism, supporting synaptic plasticity in the
Hp of apoE−/− mice [65].
It should also be noted that not all actions of Alda-1 could be interpreted unambiguously in terms
of stimulation of neurogenesis, neuroplasticity, and mitogenesis—for example, in our case, Alda-1
upregulated glycogen synthase kinase 3β (Gsk3b) and proapoptotic factor Bax mRNA expression in
the Hp of apoE−/− mice. It has been shown that increased expression of the active GSK3B form
was associated with the formation of senile plaques and neurofibrillary tangles in AD patients [66].
Clearly, further research is needed to clarify the physiological meaning of Alda-1 effects on mRNA and
protein of Gsk3b and Bax in the brain of apoE−/− mice. The main aim of our study was to elucidate the
proteomic and molecular changes in the FCx and Hp of apoE−/− mice upon treatment with Alda-1.
However, our findings cannot determine whether the changes in gene or protein expression are due to
direct or indirect effects of Alda-1 administration in apoE−/− mice. Moreover, the obvious limitation of
our study is a lack of corresponding behavioral data, which would significantly increase the impact of
the biochemical/molecular and proteomic findings. Clearly, correlation between molecular/proteomic
and functional data requires further research.
4. Materials and Methods
4.1. Animal Experiments
All animal procedures were performed in accordance to the guidelines from Directive 2010/63/EU
of the European Parliament on the protection of animals used for scientific purposes and approved
by the Jagiellonian University Ethical Committee on Animal Experiments (no. 73/2011, 8 June 2011).
Animal experiments were carried out as previously described [14]. Briefly, three groups of animals
were studied: control group (C57BL/6J mice, without treatment, on chow diet, n = 10), apoE−/− mice
from Taconic (Ejby, Denmark) (without treatment, on chow diet, n = 10), and apoE−/− mice treated
with Alda-1 (Tocris Bioscience, Bristol, UK, n = 10) at the age of eight weeks and administered to mice
for four months at a dose of 5 mg per kg of body weight per day and mixed without heating with
chow diet. At the age of six months mice were euthanized 5 min after injection of fraxiparine (1000 UI;
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Sanofi-Synthelabo, Paris, France), and the blood from the right ventricle was collected and entire brains
or hippocampi (Hp) and frontal cortices (FCx) were dissected on ice-cold glass plates.
4.2. Histology and Immunohistochemistry of the Brain
The brain tissue samples were formalin fixed, embedded in paraffin, and 2 µm paraffin sections
were stained with the hematoxilin-eosin method or used for immunohistochemistry, as previously
described [14]. The following antibodies were used: 1:100 ANTI-MAP2 (sc-20172, Santa Cruz, Dallas,
TX, USA), 1:100 ANTI-β-amyloid (A5213, Sigma, Darmstadt, Germany), 1:100 ANTI-Tau (A0024, Dako,
Denmark), and 1:100 ANTI-phospho-Tau (Ser396) (SAB4504557, Sigma, Darmstadt, Germany).
4.3. Biochemical Methods
The blood was centrifugated at 1000 g-force at 4 ◦C for 10 min and the plasma was stored in
−80 ◦C until assayed. The FCx were submerged in a PBS buffer (137 mmol/L NaCl, 2.7 mmol/L
KCl, 10 mmol/L Na2HPO4, 1.8 mmol/L KH2PO4) and homogenized using high-speed shaking (120 s)
in plastic tubes with stainless steel beads in TissueLyser II apparatus (Qiagen, Hilden, Germany).
The action of Alda-1 was assessed indirectly by the evaluation of the changes in tissue 4-HNE levels
measured by an enzyme-linked immunosorbent assay (ELISA) using commercially available kits
(MBS027502, MyBioSource, San Diego, CA, USA). The equality of variance and the normality of the
data were checked and then one-way analysis of variance (ANOVA) with the Tukey’s post-hoc test
implemented in Statistica 10.0 software (StatSoft@Polska, Krakow, Poland) was used for statistical
analysis of the data. p < 0.05 was considered as statistically significant.
4.4. Real Time (RT)-PCR
Real time (RT)-PCR experiments were performed as previously described [14]. Briefly, total
RNA was isolated from the homogenized mouse FCx and Hp using RNeasy Fibrous Tissue
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Relative gene
expression analysis in the FCx and Hp was carried out using 7900HT fast real-time PCR System
(Applied Biosystems, Foster City, CA, USA) in triplicate with GAPDH, 18S, ACTB, B2M, and
GUSB as internal reference genes. The commercially available TaqMan® Gene Expression Assays
(Applied Biosystems) were used as follows: Bax (Mm00432051_m1), Bcl-2 (Mm00477631_m1),
Bcl2l1 (Mm00437783_m1), Bdnf (Mm04230607_s1), Bmp4 (Mm00432087_m1), Neurog2
(Mm00437603_g1), Nog (Mm01297833_s1), Casp3 (Mm01195085_m1), Casp8 (Mm00802247_m1), Casp9
(Mm00516563_m1), Cdk5 (Mm00432447_g1), Cdk5r1 (Mm00438148_s1), Gsk3a (Mm01719731_g1),
Gsk3b (Mm00444911_m1), IL-1β (Mm00434228_m1), IL-6 (Mm00446190_m1), IL-10 (Rn00563409_m1),
NFkB (Mm00476361_m1), Ppargc1a (Mm01208835_m1), Pparg (Mm01184322_m1), CYTB
(Mm04225271_g1), ND1 (Mm04225274_s1), ND4L (Mm04225294_s1), COX1 (Mm04225243_g1),
COX3 (Mm04225261_g1), ATP6 (Gm10925-Mm03649417_g1), Nrf1 (Mm01135606_m1), and Tfam
(Mm00447485_m1). Reactions were performed using TaqMan® Gene Expression Master Mix (Applied
Biosystems), according to the manufacturer’s instructions. A threshold value (Ct) for each sample was
set in the exponential phase of PCR, and the ∆∆Ct method [67] was used for statistical data analysis
carried out by Data Assist v3.01 software (Applied Biosystems).
4.5. iTRAQ Method
4.5.1. Sample Preparation
The isolation of mitochondria-enriched fraction (mitochondria with synaptosomes) from
the freshly-harvested Hp and FCx was performed at 4 ◦C, as previously described [14].
Mitochondria-enriched pellets were resuspended in 0.5 mL of lysis buffer (7 M urea, 2 M thiourea, 4%
3-(3-Cholamidopropyl)dimethylammonio-1-propanesulfonate hydrate (CHAPS), 1% dithiothreitol
(DTT), the mix of protease inhibitors (Sigma)), vortexed, incubated at 25 ◦C for 30 min and then
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centrifuged at 12,000× g-force for 15 min. The protein concentration was determined in the harvested
supernatant using the Bradford method [68]. One hundred micrograms of calculated protein content
of each sample was precipitated overnight with ice-cold acetone (Sigma) (1:6 v:v). Samples were
centrifuged at 12,000× g-force for 10 min at 4 ◦C. Acetone was carefully removed and precipitates were
air-dried for 10 min. Subsequently, samples were dissolved, reduced, and alkylated, as recommended
by iTRAQ protocol (ABSciex, Framingham, MA, USA). Proteins were digested with Trypsin (Promega,
Mannheim, Germany) overnight, with 1:50 (w:w) ratio at 37 ◦C. Samples were labeled with iTRAQ
reagents as recommended by producer and ordered as follows: control: 113, 114, 115 and apoE−/−:
116, 117, 118 or apoE−/−: 113, 114, 117 and Alda-1-treated: 118, 119, 121. Labeled samples were
combined and dried in vacuum concentrator (Eppendorf, Hamburg, Germany). Next, trypsin-digested
peptides were dissolved in 5% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA) and purified with
C18 MacroSpin Columns (Harvard Apparatus, Holliston, MA, USA). Eluate was dried in a vacuum
concentrator, reconstituted in 5% ACN, 0.1% formic acid (FA), and subjected to strong cation exchange
(SCX) fractionation. Samples were loaded onto previously conditioned SCX Macrospin columns
(Harvard Apparatus), after which flow-through fraction and 11 consecutive injections of the eluent
buffer, which consisted of 5, 10, 20, 40, 60, 80, 100, 150, 200, 300, 500 mM ammonium acetate in 5%
ACN, 0.1% FA, respectively, were collected by centrifugation (1 min, 2000 g-force). Thus, the labeled
peptides from each sample were distributed across 12 SCX fractions.
4.5.2. LC-MS Analysis
Samples were concentrated on a trap column (Acclaim PepMap100 RP C18 75 µm i.d. ×2 cm
column (Thermo Scientific, Waltham, MA, USA). Each fraction was then injected on-line on PepMap100
RP C18 75 µm i.d. ×15 cm column (Thermo Scientific Dionex) and peptides were separated in 90 min
7%–55% B phase linear gradient (A phase − 2% ACN and 0.1% FA; B phase − 80% ACN and 0.1% FA)
with a flow rate of 300 nL/min by UltiMate 3000 HPLC system (Thermo Scientific Dionex) and applied
on-line to a Velos Pro (Thermo Scientific) dual-pressure ion-trap mass spectrometer. The main working
nanoelectrospray ion source (Nanospray Flex, Thermo Scientific) parameters were as follows: ion spray
voltage 1.7 kV and capillary temperature 250 ◦C. Spectra were collected in full scan mode (400–1500
Da, 50 ms AT), followed by five Higher energy Collisional Dissociation (HCD) (20 ms AT), MS/MS
scans (each consists of two microscans, 100 ms AT) of the five most intense ions from the preceding
survey full scan under dynamic exclusion criteria. Collected data were analyzed by the X!Tandem (The
GPM Organization) and Comet search algorithms and validated with PeptideProphet and iProphet
under Trans-Proteomic Pipeline (TPP) suite of software (Institute for Systems Biology, Seattle, WA,
USA). Search parameters were set as follows: taxonomy: mouse (UniProtKB/Swiss-Prot), enzyme:
trypsin, missed cleavage sites allowed: 2, fixed modification: Methylthio(C), variable modifications:
Methionine oxidation(M), iTRAQ8plex(K), iTRAQ8plex(N-term), iTRAQ8plex(Y); parent mass error
−1.5 to +3.0 Da and peptide fragment mass tolerance: 0.7 Da. Quantitative information of the peptides
data was extracted from the HCD MS2 data by Libra software under Trans-Proteomic Pipeline (TPP).
Peptide False Discovery Rate (FDR) was estimated by Mayu (TPP) and peptide identifications with
FDR below 2% were considered as correct matches. DanteR software [69] was used for statistical
analysis of iTRAQ-labeled peptides. In brief, replicate peptides were aggregated to unique peptides
while the corresponding reporter ion intensities were summed up. The dataset was normalized using
linear regression and ANOVA was performed at the peptide level using a robust linear model with
minimum 2 and maximum 500 peptides. Finally, the Benjamini and Hochberg False Discovery Rate
(FDR) correction was used to adjust p-values. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE [70] partner repository with the dataset
identifier PXD004022.
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5. Conclusions
In conclusion, despite the lack of significant morphological changes, differential proteomic
approach revealed many changes in mitochondrial protein expression, indicating the impairment of
energy metabolism, neuroplasticity, and neurogenesis in the brains of apoE−/− mice. The treatment
of apoE−/− mice with ALDH2 activator, Alda-1, led to the beneficial changes in the expression of
genes and proteins related to neuroplasticity and mitochondrial function. The accurate functional
consequences of the revealed alterations as well as the detailed mechanism of direct and indirect
Alda-1 actions require further research.
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Abbreviations
4-HNE 4-hydroxy-2-nonenal
ACN acetonitrile
AD Alzheimer’s disease
ALDH2 mitochondrial aldehyde dehydrogenase
apoE apolipoprotein E
BDNF brain-derived neurotrophic factor
BMP4 bone morphogenetic protein 4
CA2 carbonic anhydrase 2
CaMK IV calcium/calmodulin-dependent protein kinase type IV
CAPS-1 calcium-dependent secretion activator 1
CD147 basigin
CHAPS 3-(3-Cholamidopropyl)dimethylammonio-1-propanesulfonate hydrate
CNP 2′ ,3′-cyclic-nucleotide 3′-phosphodiesterase
CRMP1 collapsin response mediator protein 1
DTT dithiothreitol
EAAT2 excitatory amino acid transporter 2
FA formic acid
FCx frontal cortices
GSK3B glycogen synthase kinase 3β
GST 1-1 glutathione S-transferase Mu 1
hnRNP K heterogeneous nuclear ribonucleoprotein K
Hp hippocampi
LTP long-term potentiation
NOG noggin
NRF1 nuclear respiratory factor 1
OXPHOS oxidative phosphorylation
PARK7 Parkinson disease protein 7 homolog
PD Parkinson’s disease
SCX strong cation exchange
TFA trifluoroacetic acid
TRX thioredoxin
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